Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Source filing unavailable
Q4 2014 · —
derived · Computed from the longer spans the company filed.
Revenue$188.75M$188.75Mderived+8.4% vs Q4 2013 Net Income$33.61M$33.61Mderived−23.9% vs Q4 2013 EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived$53,210,000−19.3% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
Operating Cash Flowderived$40,920,000−35.0% Free Cash Flowderived$36,273,000−39.7% Margins · derivedOperating margin28.2%−9.7 pt vs Q4 2013
Net margin17.8%−7.5 pt vs Q4 2013